San Diego, California, United States, November 19, 2026
Adagene Inc., a clinical-stage biotechnology company focused on developing innovative antibody-based cancer immunotherapies, has announced that the first patient has been dosed in its Phase 1 clinical study of ADG138, a novel double-masked HER2×CD3 bispecific T-cell engager. The first-in-human clinical trial represents an important milestone in the company’s oncology development pipeline and marks the transition of ADG138 from preclinical research into clinical evaluation. The investigational therapy is designed to target HER2-positive advanced solid tumors by directing the patient’s immune system to recognize and destroy cancer cells. ADG138 combines an IgG1-based heterodimeric antibody format with Adagene’s proprietary SAFEbody® precision masking technology, which is designed to improve tumor-selective activation while potentially reducing unwanted immune activity in healthy tissues. The Phase 1 study will evaluate the safety and preliminary efficacy of the investigational therapy in patients with advanced cancers who have limited treatment options.
ADG138 Uses Double-Masked HER2×CD3 Technology
ADG138 is a novel bispecific T-cell engager designed to recognize two different biological targets: HER2 and CD3. HER2 is a protein expressed at elevated levels in several types of cancer, including certain breast, gastric and other solid tumors. CD3 is a protein found on T cells, which are important immune cells responsible for identifying and eliminating abnormal cells. By simultaneously targeting HER2-expressing cancer cells and CD3-positive T cells, ADG138 is designed to bring immune cells into close proximity with tumor cells and stimulate targeted cancer-cell destruction. What differentiates ADG138 from conventional bispecific T-cell engagers is its double-masking design, which uses Adagene’s proprietary SAFEbody technology. Masking peptides are covalently linked to both the HER2-binding and CD3-binding regions of the antibody. In its inactive state, the masking system is designed to limit binding to both cancer cells and T cells. Once the molecule reaches the tumor microenvironment, the masking components are designed to be removed through tumor-associated biological activity, allowing the therapeutic molecule to become activated. This approach aims to promote localized immune engagement and reduce unwanted activation outside tumor tissues.
Phase 1 Clinical Trial to Evaluate Safety and Efficacy
The first-in-human Phase 1 study of ADG138 is an open-label clinical trial designed to assess the safety, tolerability and preliminary antitumor activity of the investigational treatment in patients with HER2-positive advanced solid tumors. Another important objective is to determine the recommended Phase 2 dose for further clinical development. The dose-escalation portion of the study will begin with a starting dose of 2 mg of ADG138, with subsequent dose levels guided by emerging clinical data. The study is expected to evaluate patients who have received multiple previous treatments and whose disease has progressed following standard-of-care therapies and investigational HER2-directed antibody-drug conjugates. This patient population represents an important area of unmet medical need, particularly for individuals whose cancers no longer respond adequately to available treatment options. At this stage, the trial is primarily focused on establishing the treatment’s clinical safety profile and identifying an appropriate dose for future studies. No clinical efficacy results have been reported yet, as the program has only reached its first-patient-dosed milestone.
Preclinical Findings Support Further Clinical Development
Adagene reported encouraging findings from preclinical investigations that supported advancing ADG138 into human clinical testing. In laboratory and animal models, the double-masked design demonstrated approximately 220-fold reduced HER2 binding and more than 1,000-fold reduced CD3 binding compared with its unmasked form. Following activation in the tumor microenvironment, ADG138 demonstrated strong T-cell-mediated tumor-cell killing and tumor regression across both HER2-high and HER2-low tumor models. Notably, the investigational therapy also showed antitumor activity in a preclinical model resistant or refractory to Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate. Additional preclinical studies indicated that ADG138 was tolerated at doses more than 300 times higher than an unmasked T-cell engager, alongside markedly reduced cytokine release and a favorable pharmacokinetic profile. These findings suggest that the double-masking approach may help address certain safety and tolerability challenges associated with conventional T-cell-engaging therapies. However, these observations are based on preclinical research and will require confirmation through clinical studies.
The first-patient dosing milestone strengthens Adagene’s efforts to expand its SAFEbody precision masking platform across different antibody-based therapeutic approaches. The company is also developing muzastotug (ADG126), a masked anti-CTLA-4 antibody currently being evaluated in clinical trials. According to Adagene, clinical experience with muzastotug includes more than 250 patients dosed. The company now aims to extend its precision masking technology to bispecific T-cell engagers through ADG138. Overall, the initiation of clinical dosing represents a significant development in HER2-targeted cancer immunotherapy and highlights the potential of tumor-selective antibody engineering to advance next-generation oncology treatments.
Source: Adagene press release



